SecBot SecBot
SECBOTREPLAY Home › Report › DNLI

DNLI · Denali Therapeutics announced FDA accelerated approval of AVLAYAH™…

Denali Therapeutics Inc. · PRESS-RELEASE filed Mar 25, 2026 at 11:50 ET

At the news

BULLISHIMPACT 9/10

PRESS-RELEASE filed Mar 25, 2026 at 11:50 ET

Denali Therapeutics announced FDA accelerated approval of AVLAYAH™ (tividenofusp alfa-eknm), the first biologic therapy designed to cross the blood-brain barrier for the treatment of neurologic manifestations of Hunter syndrome (MPS II). The approval is based on biomarker reduction in cerebrospinal fluid heparan sulfate, with a confirmatory Phase 2/3 trial ongoing. Denali also received a Rare Pediatric Disease Priority Review Voucher (PRV) as part of the approval.

  • FDA granted accelerated approval to AVLAYAH™ for neurologic manifestations of Hunter syndrome (MPS II), a rare lysosomal storage disease.
  • AVLAYAH is the first FDA-approved therapy engineered to cross the blood-brain barrier via Denali’s TransportVehicle™ platform targeting the transferrin receptor.
  • Approval based on 91% reduction in cerebrospinal fluid heparan sulfate (CSF HS) by week 24 in a Phase 1/2 trial, with 93% of patients reaching normal CSF HS levels.
  • Denali received a Rare Pediatric Disease Priority Review Voucher (PRV), which can be sold or used to accelerate review of a future drug application.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access